Publications by authors named "Benilda Sanchez-Gan"

Electrical status epilepticus during sleep (ESES) is an electrographic pattern associated with specific genetic disorders, brain malformations, and use of some antiseizure medications. This case report aims to present the management of ESES in Sotos syndrome (SoS) on carbamazepine. A nine-year-old Filipino male with clinical features suggestive of overgrowth syndrome presented with febrile seizure at one year old.

View Article and Find Full Text PDF

The authors were presented with a term female neonate with a large occipital mass, who was already being treated for neonatal pneumonia at another hospital. On assessment, apart from the mass, the patient presented with an unremarkable systemic and neurological physical examination. She underwent repair of the occipital mass, which was complicated by nosocomial ventriculitis.

View Article and Find Full Text PDF
Article Synopsis
  • Pediatric epilepsy management involves challenges related to diagnosis, treatment, and the developing brain's response to interventions.
  • Broad-spectrum antiseizure medications (ASMs) that have minimal side effects and do not adversely affect cognitive function are preferred for children.
  • Perampanel is a promising ASM with broad efficacy and manageable safety, although its usage in kids is not as widely studied as in adults, prompting expert discussions on optimizing its use in treatment.
View Article and Find Full Text PDF

We report the case of a female adolescent who presented with behavioural changes. She was admitted to our institution due to worsening psychiatric and neurological symptoms, subsequently diagnosed with anti-N-methyl-D-aspartate receptor encephalitis. Additional workup was facilitated to rule out a possible underlying teratoma, but all tests turned out unremarkable.

View Article and Find Full Text PDF

Background: Perampanel is the latest anti-seizure medication introduced in the Philippines in 2015. This was initially approved as an adjunctive treatment for focal seizures and those with secondary generalization among individuals 12 years old and above. By March 2020, it has been approved also for generalized seizures and in children 4 years and above.

View Article and Find Full Text PDF